530 related articles for article (PubMed ID: 27900428)
21. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.
Kanis JA; Barton IP; Johnell O
Osteoporos Int; 2005 May; 16(5):475-82. PubMed ID: 15875093
[TBL] [Abstract][Full Text] [Related]
22. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
Roux C; Goldstein JL; Zhou X; Klemes A; Lindsay R
Osteoporos Int; 2012 Jan; 23(1):277-84. PubMed ID: 21365461
[TBL] [Abstract][Full Text] [Related]
23. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
Mok J; Brown C; Moore AEB; Min SS; Hampson G
Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
[TBL] [Abstract][Full Text] [Related]
24. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
[TBL] [Abstract][Full Text] [Related]
25. Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women.
Bilek LD; Waltman NL; Lappe JM; Kupzyk KA; Mack LR; Cullen DM; Berg K; Langel M; Meisinger M; Portelli-Trinidad A; Lang M
BMC Womens Health; 2016 Aug; 16(1):59. PubMed ID: 27576310
[TBL] [Abstract][Full Text] [Related]
26. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
27. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
Bell JM; Shields MD; Watters J; Hamilton A; Beringer T; Elliott M; Quinlivan R; Tirupathi S; Blackwood B
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010899. PubMed ID: 28117876
[TBL] [Abstract][Full Text] [Related]
28. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
Watts NB; Geusens P; Barton IP; Felsenberg D
J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
[TBL] [Abstract][Full Text] [Related]
29. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
Geller JL; Hu B; Reed S; Mirocha J; Adams JS
Endocr Pract; 2008 Apr; 14(3):293-7. PubMed ID: 18463035
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
[TBL] [Abstract][Full Text] [Related]
31. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
Ringe JD; Farahmand P; Faber H; Dorst A
Rheumatol Int; 2009 Jan; 29(3):311-5. PubMed ID: 18762944
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis.
Park SY; Kang MI; Park HM; Rhee Y; Moon SH; Yoon HK; Koh JM; Chang JS; Kim IJ; Won YY; Park YS; Choi H; Shin CS; Yoon TR; Yun SC; Chung HY;
Arch Osteoporos; 2019 Dec; 15(1):3. PubMed ID: 31820121
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
[TBL] [Abstract][Full Text] [Related]
34. Comparison of concurrent treatment with vitamin K
Tanaka S; Miyazaki T; Uemura Y; Miyakawa N; Gorai I; Nakamura T; Fukunaga M; Ohashi Y; Ohta H; Mori S; Hagino H; Hosoi T; Sugimoto T; Itoi E; Orimo H; Shiraki M
J Bone Miner Metab; 2017 Jul; 35(4):385-395. PubMed ID: 27484436
[TBL] [Abstract][Full Text] [Related]
35. Relationship between the effect of eldecalcitol and serum 25(OH)D level.
Takano T; Kondo S; Saito H; Matsumoto T;
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():124-7. PubMed ID: 24240066
[TBL] [Abstract][Full Text] [Related]
36. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women.
Ishijima M; Sakamoto Y; Yamanaka M; Tokita A; Kitahara K; Kaneko H; Kurosawa H
Calcif Tissue Int; 2009 Nov; 85(5):398-404. PubMed ID: 19795092
[TBL] [Abstract][Full Text] [Related]
37. Vitamin D status and response to treatment in post-menopausal osteoporosis.
Adami S; Giannini S; Bianchi G; Sinigaglia L; Di Munno O; Fiore CE; Minisola S; Rossini M
Osteoporos Int; 2009 Feb; 20(2):239-44. PubMed ID: 18551242
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.
Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
Osteoporos Int; 2016 Jun; 27(6):1989-98. PubMed ID: 26782683
[TBL] [Abstract][Full Text] [Related]
39. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial.
Matsumoto T; Miki T; Hagino H; Sugimoto T; Okamoto S; Hirota T; Tanigawara Y; Hayashi Y; Fukunaga M; Shiraki M; Nakamura T
J Clin Endocrinol Metab; 2005 Sep; 90(9):5031-6. PubMed ID: 15972580
[TBL] [Abstract][Full Text] [Related]
40. Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial.
Mawatari T; Ikemura S; Matsui G; Iguchi T; Mitsuyasu H; Kawahara S; Maehara M; Muraoka R; Iwamoto Y; Nakashima Y
Bone Rep; 2020 Jun; 12():100275. PubMed ID: 32462056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]